Afeyan said the company doesn’t see “any difference in the results,” among subgroups in its Covid-19 vaccine trials.
“Moderna actually slightly slowed down the trial recruitment to ensure that we had a substantial representation, and it turns out, 37% of our trials were people, were subjects, that are considered of color,” Afeyan said on CNN International Monday.
On Friday, the US Centers for Disease Control and Prevention said that hospitalization rates are significantly higher among the Black, Latino and Alaska Native or Native American populations in the US compared to Asian and White people. Hospitalization rates are about four times higher among Blacks and Latinos than Whites.
Afeyan said the company also deliberately recruited older people to be a part of the trial. Older people are more vulnerable to getting severely ill from coronavirus infections and vaccines don’t always work as well among seniors. But interim results showed people who were over 65 and older had a “robust and equivalent” response from the vaccine, Afeyan said.
“Generally, it looks like the vaccine performs broadly across all the population groups,” Afeyan said.